The reason it's very important is that the Auditor General's report in 2011 clearly referred to the time lag for people actually getting information. In fact, he said that two years is too long, so already we have a problem.
I don't know whether or not now, since 2011, the time lag has improved, but to me it's a really serious question. If the information isn't getting back to people about the adverse reactions, about what the problems are in terms of drug safety review, then really the bill is not doing the job it should do.
I think we need some very specific markers on this to demonstrate to us that the recommendations from the Auditor General are being met, and that there will be serious improvements in terms of drug safety review and the timeline that it takes.